D2l Pharma Research Solutions Private Limited - Company Profile

It is a life sciences private limited company based in Hyderabad, Telangana, India, established in 2007.
2007 Hyderabad, Telangana, India Active
Last Updated:
Access Report
About D2l Pharma Research Solutions Private Limited

D2l Pharma Research Solutions Private Limited, a active private limited company, was established on 06 July 2007 in Hyderabad, Telangana, India. Engaging in biotechnology within the professional, scientific and technical sector, it holds CIN: U24232TG2007PTC054728. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹5.00 M and a paid-up capital of ₹2.88 M.

It upholds a compliant status. Employing 47 professional, Its leadership includes Marella Ravikant (Whole-Time Director), Shekhar Gupta (Whole-Time Director), Kode Sashi Kiran (Managing Director). Past directors included Marella Ravikant, Ratna Kumari Kode, Shekhar Gupta. It holds ₹2.60 Cr open charges and ₹2.60 Cr settled loans. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at H.No: 16-11-16/75, Plot No.75 Sripuram Colony, Malakpet, Hyderabad, Telangana, 500036.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U24232TG2007PTC054728

  • Registration Number

    054728

  • Incorporation Date

    06 July 2007

  • Authorized Capital

    ₹5.00 M

  • Paid-Up Capital

    ₹2.88 M

  • ROC Code

    Roc Hyderabad

  • Listing Status

    Unlisted

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 5.00 M
  • Paid Up Capital ₹ 2.88 M
  • Company Age 18 Year, 7 Months
  • Last Filing with ROC 31 Mar 2025
  • Open Charges ₹ 2.60 Cr
  • Satisfied Charges ₹ 2.60 Cr
  • Revenue Growth **** -3.08%
  • Profit Growth **** -36.54%
  • Ebitda **** -77.50%
  • Net Worth 4.74%
  • Total Assets **** 10.36%
Company report

D2l Pharma Research Solutions Private Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into D2l Pharma Research Solutions Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at D2l Pharma Research Solutions Private Limited?
Current Directors
Name Designation Appointment Date Status
Marella Ravikant Whole-Time Director 05 Feb 2010 Current
Shekhar Gupta Whole-Time Director 18 Jan 2008 Current
Kode Sashi Kiran Managing Director 06 Jul 2007 Current
Sudheesh Kookkal Additional Director 27 Oct 2025 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Director 02 Apr 2012 Past
Pramod Abcsdd Director 10 Oct 2012 Past
Pramod Abcsdd Director 02 Apr 2012 Past
Pramod Abcsdd Director 02 Apr 2012 Past
Pramod Abcsdd Director 07 Jul 2007 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of D2L Pharma Research Solutions.

D2L Pharma Research Solutions Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 3.08% decrease. The company also saw a substantial fall in profitability, with a 36.54% decrease in profit. The company's net worth moved up by a moderate rise of 4.74%.

D2L Pharma Research Solutions revenue growth over time
D2L Pharma Research Solutions profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 -3.08%
*******
*******
*******
*******
Revenue from Operations
*******
 -8.99%
*******
*******
*******
*******
Total Assets
*******
 10.36%
*******
*******
*******
*******
Profit or Loss
*******
 -36.54%
*******
*******
*******
*******
Net Worth
*******
 4.74%
*******
*******
*******
*******
EBITDA
*******
 -77.50%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of D2L Pharma Research Solutions?

In 2023, D2L Pharma Research Solutions had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹26,000,000.00

Satisfied Charges

₹26,000,000.00

Charges Breakdown by Lending Institutions
  • Others : 2.60 Cr
Latest Charge Details
Date Lender Amount Status
30 Apr 2020 Others ₹2.60 Cr Satisfied

Explore comprehensive loan charge details -

How Many Employees Work at D2L Pharma Research Solutions?

D2L Pharma Research Solutions has a workforce of 47 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of D2L Pharma Research Solutions, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped D2L Pharma Research Solutions's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on D2L Pharma Research Solutions
Recent Activity within the Organization
  • Director Appointment

    Progress on Sudheesh Kookkal was appointed as a Additional Director was appointed as a Additional Director on 27 Oct 2025 & has been associated with this company since 4 months 7 days . was documented.

  • Annual General Meeting

    Progress on D2L Pharma Research Solutions Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was documented.

  • Charges

    Progress on A charge registered on 30 Apr 2020 via Charge ID 100337127 with Others was fully satisfied on 03 Jun 2025. was documented.

  • Balance Sheet

    Progress on D2L Pharma Research Solutions Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad. was documented.

  • Charges

    A charge with Others of Rs. 26.00 M registered on 30 Apr 2020 with Charge ID 100337127 was modified on 30 Oct 2023. was recorded as a recent event.

  • Charges

    Progress on A charge with Others amounted to Rs. 26.00 M with Charge ID 100337127 was registered on 30 Apr 2020. was documented.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of D2l Pharma Research Solutions Private Limited?

The CIN of D2l Pharma Research Solutions Private Limited is U24232TG2007PTC054728.

Where is D2l Pharma Research Solutions Private Limited headquartered?

D2l Pharma Research Solutions Private Limited is headquartered at H.No: 16-11-16/75, Plot No.75 Sripuram Colony, Malakpet, Hyderabad, Telangana, 500036.

When was D2l Pharma Research Solutions Private Limited incorporated?

D2l Pharma Research Solutions Private Limited was incorporated on 06 July 2007.

Who are the current directors of D2l Pharma Research Solutions Private Limited?

The current directors of D2l Pharma Research Solutions Private Limited are

What is the primary industry of D2l Pharma Research Solutions Private Limited?

The primary industry of D2l Pharma Research Solutions Private Limited is Professional, Scientific And Technical.

Is D2l Pharma Research Solutions Private Limited a listed company?

D2l Pharma Research Solutions Private Limited is unlisted.

What is the capital structure of D2l Pharma Research Solutions Private Limited?

The authorized capital of D2l Pharma Research Solutions Private Limited is ₹5.00 M, and the paid-up capital is ₹2.88 M.

What is the compliance status of D2l Pharma Research Solutions Private Limited?

The compliance status of D2l Pharma Research Solutions Private Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available